Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided azacitidine after allogeneic stem cell transplantation in MDS
2024-511651-17-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and acute myeloid leukemia (AML), sponsored by Karolinska University Hospital. Primary endpoint: Clinical events at 12 months from verified MRD positivity. Planned start Mar 2024; status: authorised.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-511651-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511651-17-00.